SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Elusys Therapeutics, Inc. Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax